At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 37 enrolled
Drug / intervention
ASONEP (sonepcizumab/LT1009)biological
Likely dose
ASONEP (sonepcizumab/LT1009) 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Open-Label, Single-Arm, Phase 1, Dose Escalation Study of ASONEP (Sonepcizumab/LT1009) Administered as a Single Agent Weekly to Subjects With Refractory Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating ASONEP (sonepcizumab/LT1009) for Solid Tumors. Completed, enrolled 37 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine the safety, tolerability and highest dose of ASONEP that can safely be administered to patients with cancer who are no longer being helped by standard treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedApr 2008
Primary CompletionDec 2011
TodayJul 2026
First PostedApr 18, 2008
Enrollment StartApr 1, 2008
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 18.2 years ago
Interventions
ASONEP (sonepcizumab/LT1009)biological
ASONEP \[sonepcizumab/LT1009\] is supplied as a colorless,particulate-free, pH 6.5, sterile solution containing approximately 10 mg/mL or 20 mg/mL of drug. The candidate drug is intended for single intravenous (iv) use administered over 90 minutes on a weekly basis.